MCID: PDT040
MIFTS: 30

Pediatric Hypertension malady

Categories: Rare diseases

Aliases & Classifications for Pediatric Hypertension

Aliases & Descriptions for Pediatric Hypertension:

Name: Pediatric Hypertension 50

Classifications:



Summaries for Pediatric Hypertension

MalaCards based summary : Pediatric Hypertension is related to iris disease and prostate neuroendocrine neoplasm. An important gene associated with Pediatric Hypertension is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Peptide hormone metabolism and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Mycophenolic acid and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include testes and kidney.

Related Diseases for Pediatric Hypertension

Graphical network of the top 20 diseases related to Pediatric Hypertension:



Diseases related to Pediatric Hypertension

Symptoms & Phenotypes for Pediatric Hypertension

Drugs & Therapeutics for Pediatric Hypertension

Drugs for Pediatric Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 1 24280-93-1 446541
2
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1 128794-94-5 5281078
3
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
4
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2 738-70-5 5578
5
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
7
Ibuprofen Approved Phase 4 15687-27-1 3672
8
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
9
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 11103-57-4, 68-26-8 445354
11
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
12
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
13 Analgesics Phase 4,Phase 2,Phase 3,Early Phase 1
14 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4,Phase 3,Phase 2
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
21 Antitubercular Agents Phase 4,Phase 3
22 vitamin d Phase 4
23
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Cyclooxygenase 2 Inhibitors Phase 4
25 Cyclooxygenase Inhibitors Phase 4
26 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Early Phase 1
28 Trace Elements Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Vitamins Phase 4,Phase 2
31 Anti-Inflammatory Agents Phase 4,Phase 2
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4
33 Liver Extracts Phase 4,Phase 2,Phase 3
34 Retinol palmitate Phase 4,Phase 2
35 Micronutrients Phase 4
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Bone Density Conservation Agents Phase 4
38 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3
39 Ergocalciferols Phase 4
40 retinol Nutraceutical Phase 4,Phase 2
41 Vitamin D2 Nutraceutical Phase 4
42 Calciferol Nutraceutical Phase 4
43
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
44
Nitric Oxide Approved Phase 3,Phase 2,Phase 1 10102-43-9 145068
45
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
46
Metformin Approved Phase 3,Phase 1,Phase 2 657-24-9 14219 4091
47
Enalapril Approved, Vet_approved Phase 3,Phase 2 75847-73-3 5362032 40466924
48
Enalaprilat Approved Phase 3,Phase 2 76420-72-9 6917719
49
Losartan Approved Phase 3,Phase 2 114798-26-4 3961
50
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833

Interventional clinical trials:

(show top 50) (show all 200)
id Name Status NCT ID Phase
1 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
2 Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Unknown status NCT01895894 Phase 4
3 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Unknown status NCT02357758 Phase 4
4 Treatment of Pediatric Hypertension With Altace Trial Completed NCT00044265 Phase 4
5 Comparison of Immunosuppression Protocols After LTx in Children Completed NCT00195988 Phase 4
6 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
7 Efficacy of Vitamin D Supplementation in Obese Children Enrolling by invitation NCT02956408 Phase 4
8 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
9 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3
10 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3
11 A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension Completed NCT00171028 Phase 3
12 A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension Completed NCT02451150 Phase 3
13 Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age Completed NCT00244634 Phase 3
14 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD Completed NCT01617681 Phase 3
15 Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects Completed NCT00255528 Phase 3
16 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed NCT00255502 Phase 3
17 Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age Completed NCT00244621 Phase 3
18 Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age Completed NCT00244595 Phase 3
19 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01150357 Phase 3
20 A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age Completed NCT00171041 Phase 3
21 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01151410 Phase 3
22 Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients Completed NCT01007994 Phase 2, Phase 3
23 Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension Completed NCT00061516 Phase 3
24 Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension Completed NCT00061542 Phase 3
25 Bosentan in Children With Pulmonary Arterial Hypertension Completed NCT00319267 Phase 3
26 Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension Completed NCT01223352 Phase 3
27 Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337) Completed NCT00756938 Phase 3
28 FUTURE 3 Study Extension Completed NCT01338415 Phase 3
29 Bosentan in Children With Pulmonary Arterial Hypertension Extension Study Completed NCT00319020 Phase 3
30 Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) Completed NCT00690612 Phase 3
31 Sedation With Dexmedetomidine During Cardiac Catheterization Completed NCT01072643 Phase 2, Phase 3
32 Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery Completed NCT01310751 Phase 2, Phase 3
33 The Long-Term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years Completed NCT00147615 Phase 3
34 Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD) Completed NCT01598441 Phase 3
35 A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children. Completed NCT00147589 Phase 3
36 Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Completed NCT01652664 Phase 3
37 An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) Completed NCT00568178 Phase 3
38 Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age Completed NCT01365481 Phase 3
39 Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients Completed NCT00221845 Phase 3
40 Trabeculectomy With MMC Versus Ahmed Glaucoma Implant for Treatment of Pediatric Aphakic Glaucoma Completed NCT00371072 Phase 2, Phase 3
41 A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children Completed NCT00159874 Phase 3
42 A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma. Completed NCT00716859 Phase 3
43 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed NCT00741156 Phase 3
44 Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension Completed NCT00660179 Phase 3
45 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Completed NCT01106014 Phase 3
46 Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Completed NCT01959828 Phase 3
47 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Completed NCT00319982 Phase 2, Phase 3
48 Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome Completed NCT01743001 Phase 3
49 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Completed NCT00081328 Phase 3
50 Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00981838 Phase 3

Search NIH Clinical Center for Pediatric Hypertension

Genetic Tests for Pediatric Hypertension

Anatomical Context for Pediatric Hypertension

MalaCards organs/tissues related to Pediatric Hypertension:

39
Testes, Kidney

Publications for Pediatric Hypertension

Articles related to Pediatric Hypertension:

(show top 50) (show all 114)
id Title Authors Year
1
Definition of pediatric hypertension: are blood pressure measurements on three separate occasions necessary? ( 28077857 )
2017
2
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27754136 )
2016
3
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27643124 )
2016
4
Pharmacologic Treatment of Pediatric Hypertension. ( 27048353 )
2016
5
Pharmacologic Management of Pediatric Hypertension. ( 26597490 )
2016
6
Re: Pediatric Hypertension and Cardiac Hypertrophy. ( 26739585 )
2016
7
Vascular Aging: Lessons From Pediatric Hypertension. ( 27040097 )
2016
8
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27754179 )
2016
9
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27643136 )
2016
10
Pediatric Hypertension: Are Pediatricians Following Guidelines? ( 27659546 )
2016
11
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27643063 )
2016
12
In-Clinic Blood Pressure Prediction of Normal Ambulatory Blood Pressure Monitoring in Pediatric Hypertension Referrals. ( 27205889 )
2016
13
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, and Assessment of Risk of Pediatric Hypertension. ( 27118292 )
2016
14
Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. ( 27940711 )
2016
15
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27754169 )
2016
16
Assessment of Left Ventricular Mass and Hypertrophy by Cardiovascular Magnetic Resonance Imaging in Pediatric Hypertension. ( 26988578 )
2016
17
Diagnosis of primary versus secondary pediatric hypertension. ( 25594296 )
2015
18
The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension. ( 25794952 )
2015
19
Recent clinical and translational advances in pediatric hypertension. ( 25712720 )
2015
20
Cardiovascular target organ damage could have been detected in sustained pediatric hypertension. ( 26024395 )
2015
21
Abnormalities of vascular structure and function in pediatric hypertension. ( 26275663 )
2015
22
Is Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension? ( 26140344 )
2015
23
Pediatric hypertension: a growing problem. ( 25634711 )
2015
24
Pediatric hypertension: a pharmacological review. ( 25898872 )
2015
25
Racial Differences of Pediatric Hypertension in Relation to Birth Weight and Body Size in the United States. ( 26176843 )
2015
26
Pediatric hypertension in the Eastern Province of Saudi Arabia. ( 25987114 )
2015
27
Pediatric hypertension: a pharmacological review. ( 25898873 )
2015
28
Hypertension editors' picks: pediatric hypertension. ( 25855321 )
2015
29
Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity. ( 26389821 )
2015
30
Essential pediatric hypertension: defining the educational needs of primary care pediatricians. ( 25063988 )
2014
31
U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms? ( 24720583 )
2014
32
Pediatric hypertension: often missed and mismanaged. ( 24701598 )
2014
33
Clinical predictors and impact of ambulatory blood pressure monitoring in pediatric hypertension referrals. ( 25065681 )
2014
34
Pediatric hypertension: An update on a burning problem. ( 24944755 )
2014
35
Gene polymorphisms of adducin GLY460TRP, ACE I/D, AND AGT M235T in pediatric hypertension patients. ( 25262176 )
2014
36
Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. ( 27129124 )
2014
37
Response to "U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms?". ( 24720549 )
2014
38
Autonomic nervous system dysregulation in pediatric hypertension. ( 24633841 )
2014
39
Pediatric Hypertension Specialists' Perspectives About Adolescent Hypertension Management: Implications for Primary Care Providers. ( 25398627 )
2014
40
Concordance of Measures of Left-Ventricular Hypertrophy in Pediatric Hypertension. ( 24253610 )
2013
41
The changing face of pediatric hypertension in the era of the childhood obesity epidemic. ( 23138756 )
2013
42
Serum urate: a biomarker or treatment target in pediatric hypertension? ( 23736817 )
2013
43
Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. ( 24337365 )
2013
44
Pediatric Hypertension: The Year in Review. ( 23960265 )
2013
45
Executive Function and Cerebrovascular Reactivity in Pediatric Hypertension. ( 23877480 )
2013
46
The increasing burden of pediatric hypertension. ( 22710647 )
2012
47
Pediatric hypertension: a cause for concern. ( 22343958 )
2012
48
Recent advances in pediatric hypertension. ( 22672086 )
2012
49
Valsartan use in pediatric hypertension. ( 21453020 )
2011
50
Pharmacotherapy review of chronic pediatric hypertension. ( 21982385 )
2011

Variations for Pediatric Hypertension

Expression for Pediatric Hypertension

Search GEO for disease gene expression data for Pediatric Hypertension.

Pathways for Pediatric Hypertension

GO Terms for Pediatric Hypertension

Biological processes related to Pediatric Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.43 ACE AGT
2 regulation of blood pressure GO:0008217 9.4 ACE AGT
3 blood vessel remodeling GO:0001974 9.37 ACE AGT
4 positive regulation of protein tyrosine kinase activity GO:0061098 9.32 ACE AGT
5 regulation of vasoconstriction GO:0019229 9.26 ACE AGT
6 angiotensin maturation GO:0002003 9.16 ACE AGT
7 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE AGT
8 regulation of renal output by angiotensin GO:0002019 8.62 ACE AGT

Sources for Pediatric Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....